News and Announcements
Phylogica and cubist collaborate to evaluate antimicrobial phylomers
- Published July 26, 2013 9:07AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
PERTH, AUSTRALIA: July 25th 2013. Phylogica Ltd (ASX: PYC, XETRA: PH7) a leading Australian peptide drug discovery company, announces a collaboration with Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) to evaluate several of its antimicrobial Phylomers in models of multi-drug resistant bacterial infections.
“I am delighted to have the opportunity to collaborate with one of the world’s leading developers of antimicrobial drugs,” said Phylogica’s Chief Scientific Officer Dr Paul Watt. “Through this collaboration, we hope that Phylogica’s antimicrobial Phylomers will support Cubist’s ongoing work to discover and develop new antibiotics to address the growing global health threat of antibiotic resistance. In Phylogica’s own assays, these antimicrobials have shown activity against multi-resistant isolates of Gram- negative organisms, which are a major cause of deaths from hospital acquired infections of burn wounds”.
To read the full ASX announcement, please download the document below.